Tatva Chintan Pharma Chem Analyst Review May 2026

This Tatva Chintan Pharma Chem analyst review for May 2026 covers the key data investors need for TATVA at its current price of Rs 1,050. Tatva Chintan Pharma Chem (NSE: TATVA) is a specialty chemicals company with a market capitalisation of approximately Rs 2,200 crore, specialising in structure directing agents (SDAs) for catalysts and pharmaceutical intermediates. The analyst consensus target of Rs 1,200 implies meaningful upside, and this Tatva Chintan Pharma Chem analyst review examines technical levels, business segments, valuation, and key risks for TATVA through FY27.

Click Here – Get Free Investment Predictions

Tatva Chintan Pharma Chem Company Snapshot May 2026

Tatva Chintan’s SDAs for zeolite synthesis, phase transfer catalysts, and pharma/agrochemical intermediates are niche high-value products with limited global competition. US and European export growth drives margin expansion. The table below summarises the key data referenced in this Tatva Chintan Pharma Chem analyst review.

Parameter	Value
NSE Ticker	TATVA
Sector	Specialty Chemicals – Structure Directing Agents
CMP (May 2026)	Rs 1,050
52 Week High	Rs 1,550
52 Week Low	Rs 920
Market Cap	Rs 2,200 Crore
Trailing P/E	45x
Analyst Consensus Target	Rs 1,200
Bull Case Target	Rs 1,600
Bear Case Target	Rs 900

Analyst Insight in This Tatva Chintan Pharma Chem Analyst Review

Associate Director Kunal Singla suggests watching Tatva Chintan Pharma Chem closely in May 2026. At Rs 1,050, Kunal Singla flags Specialty Chemicals – Structure Directing Agents sector dynamics as the primary driver for TATVA’s near-term price action. He notes support in the Rs 938 to Rs 998 zone and flags any sustained close above Rs 1113 as a positive signal. Kunal Singla’s perspective on Tatva Chintan Pharma Chem adds professional analysis to this Tatva Chintan Pharma Chem analyst review and is not a buy recommendation.

Technical Analysis in This Tatva Chintan Pharma Chem Analyst Review

At Rs 1,050, TATVA is trading within its 52-week band of Rs 920 to Rs 1,550. The current position relative to the 52-week high and low is the first layer of technical context for any entry or exit decision. Momentum indicators including the 14-day RSI, MACD crossover, and volume trends are useful secondary signals to monitor alongside the Nifty 50 direction.

Near-term support is identified in the Rs 938 to Rs 998 band while resistance is seen in the Rs 1113 to Rs 1125 zone. A sustained move above Rs 1113 could open the path toward the analyst consensus target of Rs 1,200 as outlined in this Tatva Chintan Pharma Chem analyst review.

Screen the best stocks on the Univest Screener.

Key Support and Resistance Levels

• Support Zone: Rs 938 to Rs 998 – investors tracking this Tatva Chintan Pharma Chem analyst review should watch for stabilisation or a bounce in this range as a potential accumulation signal for TATVA.
• Resistance Zone: Rs 1113 to Rs 1125 – a sustained close above Rs 1113 would be a positive breakout signal worth flagging in this Tatva Chintan Pharma Chem analyst review.
• Medium-Term Target: The analyst consensus of Rs 1,200 represents the base-case upside scenario in this Tatva Chintan Pharma Chem analyst review.

Business Segment Analysis

Structure Directing Agents (SDAs – Global Niche Leader)

This is the primary revenue and margin driver for Tatva Chintan Pharma Chem, directly supporting the earnings trajectory toward the consensus target of Rs 1,200.

Phase Transfer Catalysts (PTC)

This segment adds scale and diversification to Tatva Chintan Pharma Chem’s business model and is a meaningful EPS contributor through FY27 and FY28.

Pharmaceutical and Agrochemical Intermediates

This represents the medium-term growth frontier for Tatva Chintan Pharma Chem and a key re-rating catalyst over the next 12 to 24 months.

Valuation in This Tatva Chintan Pharma Chem Analyst Review

At Rs 1,050, Tatva Chintan Pharma Chem trades at a trailing P/E of 45x. This Tatva Chintan Pharma Chem analyst review presents three scenarios: a bull case of Rs 1,600 on strong earnings delivery and sector tailwinds, a base case of Rs 1,200 at analyst consensus, and a bear case of Rs 900 if macro headwinds persist. Q1 FY27 results will be the first key checkpoint for this Tatva Chintan Pharma Chem analyst review.

Scenario	Target Price	Key Condition
Bull Case	Rs 1,600	Strong earnings delivery and sector re-rating
Base Case (Consensus)	Rs 1,200	Moderate growth, analyst consensus estimate
Bear Case	Rs 900	Earnings miss or macro headwinds

Trade Outlook for Tatva Chintan Pharma Chem

Based on the technical and fundamental analysis in this Tatva Chintan Pharma Chem analyst review, investors might watch TATVA near the support zone of Rs 938 to Rs 998 for potential opportunities. A flag above Rs 1113 could suggest improving momentum toward Rs 1,200. This article uses watch-and-flag language only and does not constitute a trade recommendation.

Key Risks for Tatva Chintan Pharma Chem in FY27

A well-rounded Tatva Chintan Pharma Chem analyst review must assess downside risks. Key risks for Tatva Chintan Pharma Chem include a macro slowdown affecting Specialty Chemicals – Structure Directing Agents sector demand, input cost or regulatory headwinds compressing margins, continued FII selling from Indian equities, and earnings estimate downgrades if Q1 FY27 guidance disappoints. Market conditions may change rapidly. This analysis is not financial advice; investors should perform their own due diligence before investing in TATVA.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Conclusion: Tatva Chintan Pharma Chem Analyst Review Verdict for 2026

This Tatva Chintan Pharma Chem analyst review concludes that at Rs 1,050, TATVA offers a defined risk-reward with a consensus target of Rs 1,200. The 52-week range of Rs 920 to Rs 1,550 provides context on the current entry point. Use this Tatva Chintan Pharma Chem analyst review as a research starting point and consult a SEBI-registered financial advisor before making any investment decisions on TATVA.

Frequently Asked Questions: Tatva Chintan Pharma Chem Analyst Review 2026

What is the analyst target for Tatva Chintan Pharma Chem in 2026?

The analyst consensus target is Rs 1,200, with a bull case of Rs 1,600 and a bear case of Rs 900. This Tatva Chintan Pharma Chem analyst review recommends monitoring Q1 FY27 earnings for confirmation.

Is Tatva Chintan Pharma Chem a good investment at Rs 1,050?

At Rs 1,050 with a P/E of 45x and a consensus target of Rs 1,200, this Tatva Chintan Pharma Chem analyst review is constructive for medium to long-term investors in the Specialty Chemicals – Structure Directing Agents sector. Always consult a SEBI-registered advisor before investing.

What is Tatva Chintan Pharma Chem’s 52-week high and low?

The 52-week high is Rs 1,550 and the 52-week low is Rs 920. At Rs 1,050, TATVA is positioned within this range as detailed in this Tatva Chintan Pharma Chem analyst review.

What are the key risks for Tatva Chintan Pharma Chem?

Key risks include macro slowdown, input cost pressures, FII selling, and regulatory changes in the Specialty Chemicals – Structure Directing Agents sector, all assessed in this Tatva Chintan Pharma Chem analyst review.

Where can I track live data for Tatva Chintan Pharma Chem?

Track Tatva Chintan Pharma Chem’s live price and analyst targets on the Univest Screener alongside professional financial advice to complement this Tatva Chintan Pharma Chem analyst review.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.